In breast cancer cells medroxyprogesterone acetate (MPA) treatment for 6 days increased glucose uptake and fatty acid synthase (FASN) and activation of stearoyl-CoA desaturase-1 (SCD-1). Here, SCD is linked to breast carcinoma.